AAREYDRUGSBSEAarey Drugs & Pharmaceuticals LtdMinimalNeutral
Announced Sat, 30 May · 20:19 IST

As per attachment

AAREYDRUGS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.1%1-day move
₹77.50
prior close
₹77.99
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+3.2+3.3+3.9+1.9-2.1-1.9+0.0+1.3+2.9+2.9+13.3+14.0
Up moveDown movePending
AI summary

The Practicing Company Secretary Ashika Shetty has submitted the Annual Secretarial Compliance Report for FY 2025-26 identifying 9 compliance violations. Key issues include: (1) failure to disclose shareholding pattern for allotment of 50 lakh warrants on 23 May 2025, (2) non-disclosure of 7.09% promoter share sale by Suraj Tradelinks under SEBI Takeovers and Insider Trading regulations, (3) failure to indicate lock-in status compliance for warrant allottees, (4) non-publication of audited financial results in newspaper in SEBI-prescribed format, (5) delayed XBRL filing of integrated financial results, (6) non-filing of related party transaction disclosure for H1 FY26 (BSE and NSE imposed penalties), (7) non-filing of statement of deviation of preferential allotment proceeds, and (8) inadequate disclosure while seeking omnibus related party approval. The report also notes previous year non-compliances regarding warrant lock-in delays and preferential allotment disclosures remain unresolved.

Likely market impact

This report reveals significant and repeated regulatory non-compliance by the company across multiple SEBI regulations. Shareholders should note that the company has not fully regularised past violations and continues to face compliance gaps, indicating weak corporate governance. BSE and NSE have already imposed penalties for related party transaction non-disclosure.